Loading clinical trials...
Loading clinical trials...
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in particip...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Avistone Biotechnology Co., Ltd.
NCT06716138 · Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, and more
NCT06974812 · Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06107686 · NSCLC, Breast Cancer, and more
NCT05205109 · Locally Advanced or Metastatic Solid Tumors
University of California, San Diego
San Diego, California
Sarah Cannon Research Institute
Denver, Colorado
Advent Health
Orlando, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions